Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Frequently asked questions
What sector does Valion Bio Inc (VBIO) operate in?
Valion Bio Inc belongs to the Other sector and operates in the Biotechnology industry.
What is Valion Bio Inc (VBIO) current stock price?
As of the latest data, Valion Bio Inc stock price is $0.84, with a previous close of $0.94. Valion Bio Inc lost -$0.10 in the last trading session, representing a -10.64% loss.
What is Valion Bio Inc (VBIO) current market capitalization?
Valion Bio Inc market cap is approximately 745.57 thousand.
What is Valion Bio Inc (VBIO) Earnings Per Share (EPS)?
The trailing EPS is -$182.88.
What is Valion Bio Inc (VBIO) EBITDA?
Valion Bio Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.07 million.
Does Valion Bio Inc (VBIO) pay dividends?
No. Valion Bio Inc does not pay a dividend.
When is Valion Bio Inc (VBIO) next earnings report?
Valion Bio Inc is expected to release its next earnings report on September 30, 2026.
What is Valion Bio Inc (VBIO) beta (volatility) score?
Valion Bio Inc has a beta of 1.792, suggesting it is more volatile than the market.
